Compare Sherwin-Williams Company (The) Common Stock (SHW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sherwin-Williams Company (The) Common Stock vs GeneDx Holdings Corp — how do they compare? Sherwin-Williams Company (The) Common Stock trades at $325.43 (market cap $78.78B), while GeneDx Holdings Corp trades at $68.61 (market cap $2.04B). The key difference: Sherwin-Williams Company (The) Common Stock is far larger — about 38.6× GeneDx Holdings Corp's market cap, and Sherwin-Williams Company (The) Common Stock pays a 0.99% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| SHW | WGS | |
|---|---|---|
Market Cap | $78.78B | $2.04B |
Volume | 1,403,311 | 962,082 |
Sector | Basic Materials | Health |
52-Week High | $372.60 | $167.51 |
52-Week Low | $293.00 | $34.51 |
Enterprise Value | $92.71B | $2.08B |
Dividend Yield | 0.99% | — |
Typical Hold Time | — | 20 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sherwin-Williams (SHW) trades at $324.10, up 1.21% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows neutral technical signals but maintains robust fundamentals with 65.12% ROE and expanding manufacturing capacity. Recent facility expansions in Statesville enhance production capabilities, positioning the company for continued market share gains.
Outlook remains positive with analyst consensus at Buy (57.9%) and $383.64 price target, though high valuation multiples (P/E 29.9) and competitive pressures present risks. Earnings growth and strategic investments support upside potential, while margin compression and economic sensitivity warrant monitoring.
GeneDx Holdings (WGS) trades at $64.96, up 1.79% today, showing mixed technical signals with a bearish moving average trend but bullish oscillators. Fundamentally, the company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows a net loss of -$106M. Recent news highlights product launches and CEO recognition, while analyst sentiment remains strongly positive with 91% buy ratings.
The outlook for WGS is cautiously optimistic with strong analyst support and operational improvements, but significant risks persist including negative profitability margins and high valuation multiples. The consensus price target of $81 suggests 25% upside potential, though investors should monitor cash flow trends and competitive pressures in the genomics diagnostics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Sherwin-Williams Company (The) Common Stock
The Sherwin-Williams Company manufactures, develops, and distributes paints, coatings, and related products through three segments: Paint Stores Group, operating more than 4,900 company-owned stores selling Sherwin-Williams-branded products; Consumer Brands Group, selling brands such as Valspar, Dutch Boy, Krylon, and Minwax through mass merchandisers and home centers; and Performance Coatings Group, supplying industrial, construction, and transportation coatings in more than 120 countries.
Read more on SHW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
